Drug intelligence / Profile preview

Protykin

Development stage
Unknown
Lead developer
InterHealth Nutraceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Protykin is a standardized natural extract derived from *Polygonum cuspidatum* (Japanese knotweed), developed by InterHealth Nutraceuticals (now part of Lonza). It is characterized by a high concentration of bioactive compounds, specifically standardized to contain 20% trans-resveratrol and 10% emodin. As a dietary supplement ingredient, it is primarily utilized for its antioxidant and phytoestrogenic properties. Research indicates its potential in providing cardioprotection through free radical scavenging activity during ischemic injury. Additionally, it is marketed for managing menopausal symptoms, such as hot flashes and mood swings, by helping to maintain normal estrogen activity and supporting healthy bone density. It is typically used as an ingredient in various formulations for cardiovascular health and menopausal support rather than as an approved pharmaceutical drug.

Brand names
Protykin
Other names
Polygonum cuspidatum extract
02

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on Protykin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protykin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call